Spruce Biosciences, Inc. (SPRB), Tuesday announced the acquisition of tralesinidase alfa enzyme replacement therapy or TA-ERT for the treatment of Sanfilippo Syndrome Type B or MPS IIIB, a neurodegenerative and fatal genetic disease.
The company stated that TA-ERT has significantly and durably normalized cerebral spinal fluid heparan sulfate non-reducing end levels in clinical trials over a five-year period.
Further, the U.S. Food and Drug Administration stated that HS-NRE could be used as a biomarker that may reasonably predict clinical benefit and serve as a basis for accelerated approval.
Based on the encouraging data, Spruce plans to submit a Biologics License Application Submission to FDA for TA-ERT in the first half of 2026.
Looking ahead, Spruce intends to seek U.S. accelerated approval of TA-ERT for MPS IIIB based on existing non-clinical and clinical data.
Moreover, the company seeks to commercialize TA-ERT and its other investigational products throughout the international markets, including North America, the European Union, the United Kingdom, Latin America, Turkey, and Asia.
Notably, TA-ERT has received fast-track designation, rare pediatric disease designation, and orphan drug designation in the U.S. and EU.
As of December 31, 2024, Spruce had cash and cash equivalents of $38.8 million. The company expects its cash runway to fund its current operating plan through the end of 2025.
In the pre-market hours, Spruce's stock is trading at $0.26, down 17.72 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.